Military Service Can Bring Melanoma Danger
TUESDAY, March 12, 2024 — U.S. military veterans, especially those who served in the Air Force, are at high risk for one of the deadliest skin cancers, melanoma.The risk owes to work hazards associated with service in countries near the equator... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 12, 2024 Category: General Medicine Source Type: news

TIL for Melanoma: What Are the Costs and Challenges? TIL for Melanoma: What Are the Costs and Challenges?
A new FDA-approved treatment for melanoma has hit the market with a high price, and clinicians are working with insurers to determine out-of-pocket costs for patients.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Does breast radiation therapy raise risk of skin cancer?
Radiation therapy for breast cancer treatment leads to an increased risk of skin cancer, according to research published March 8 in JAMA Network Open. A team led by Shawheen Rezaei from Stanford University found that the risk of non-keratinocyte skin cancer diagnosis such as melanoma and hemangiosarcoma after breast cancer treatment with radiation was more than 50% higher. “Although occurrences of non-keratinocyte skin cancers are rare, physicians should be aware of this elevated risk to help inform follow-up care,” the Rezaei team wrote. While breast cancer treatment strategies have improved over the decades, survi...
Source: AuntMinnie.com Headlines - March 11, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Womens Imaging Breast Breast Imaging Source Type: news

New NCCN Melanoma Guidelines Capture Evolving Best Practice New NCCN Melanoma Guidelines Capture Evolving Best Practice
NCCN guidelines for cutaneous melanoma, issued in February, capture evolving data for both diagnosis and treatment, diverging incrementally from 2019 AAD guidelines.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 9, 2024 Category: Internal Medicine Tags: Dermatology Source Type: news

BAMF Health to partner with Corewell Health
BAMF Health and Corewell Health Haworth Innovative Therapeutics Clinic plan to collaborate on a clinical trial to test targeted radiation therapy for cancer patients. The phase I trial is sponsored by Y-mAbs Therapeutics and will include both adolescent and adult patients with recurrent or resistant small-cell lung cancer, sarcoma, and malignant melanoma. Trial participants will receive tumor-targeting treatment with an antibody that binds to a protein called GD-2 on the surface of the cancer cells, then a radioisotope infusion that binds to the antibody and delivers the radiation to cancer cells, BAMF Health said. (Sourc...
Source: AuntMinnie.com Headlines - March 4, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Newly Approved Cell Therapy For Advanced Melanoma, Amtagvi, Is A Potential Breakthrough
A confirmatory Phase 3 trial is ongoing to verify Amtagvi ’s clinical benefit in advanced melanoma patients. If confirmed, Amtagvi will be an important breakthrough. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 4, 2024 Category: Pharmaceuticals Authors: Joshua Cohen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news

Kimmtrak Tebentafusp Sales Increase By 64% In 2023
In the battle against melanoma, Kimmtrak has emerged as a groundbreaking treatment that offers an innovative approach of treatment with significant commercial potential. Although Kimmtrak is currently only approved for the treatment of uveal melanoma, clinical trials are being conducted to…#tebentafusp #immunocore (Source: Reuters: Health)
Source: Reuters: Health - February 29, 2024 Category: Consumer Health News Source Type: news

What ’s The Incidence Rate of a Second Primary Melanoma? What ’s The Incidence Rate of a Second Primary Melanoma?
The findings may have potential implications for more personalized surveillance of patients with melanoma, the authors said.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 29, 2024 Category: Internal Medicine Tags: Dermatology Source Type: news

Delayed Melanoma Care During Pandemic Proved Costly
TUESDAY, Feb. 27, 2024 -- Delays in melanoma diagnoses due to COVID-19 pandemic lockdowns were associated with a significant burden, including years of life lost and costs, according to a study published online Feb. 16 in JAMA Network... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2024 Category: Pharmaceuticals Source Type: news

FDA Approves 1st T-Cell Therapy For Melanoma
Authored by Amie Dahnke via The Epoch Times (emphasis ours), Melanoma cancer patients with solid tumors can turn to a new treatment thanks to the U.S. Food and Drug Administration’s (FDA) approval of a new class of immunotherapy. The new treatment may…#fda #amiedahnke #epochtimes #melanoma #amtagvi #samantharguild #aim #melanomafoundation #petermarks #hispanic (Source: Reuters: Health)
Source: Reuters: Health - February 23, 2024 Category: Consumer Health News Source Type: news

News at a glance: Protecting a queen, cell therapy for solid tumors, and a UV telescope
CONSERVATION U.S. protects iconic marine snail The queen conch, a large marine snail known for its showy shell and delectable flesh, has been added to the U.S. government’s list of species threatened with extinction. Scientists at the National Oceanic and Atmospheric Administration (NOAA) said the species ( Strombus gigas , pictured), which is native to the Caribbean region and grows up to 35 centimeters long, needs protection because populations are sparse, scattered, and heavily overfished. NOAA’s listing decision, issued on 14 February, has no immediate impact but authorizes the age...
Source: ScienceNOW - February 22, 2024 Category: Science Source Type: news

Iovance stock soars on FDA approval of its melanoma gene therapy
Iovance has its gene therapy manufacturing plant at the Philadelphia Navy Yard. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 20, 2024 Category: Biotechnology Authors: John George Source Type: news

Amtagvi Approved by the FDA for Treatment of Advanced Melanoma
TUESDAY, Feb. 20, 2024 -- Amtagvi (lifileucel) has been approved by the U.S. Food and Drug Administration for the treatment of advanced melanoma. Amtagvi becomes the first cellular therapy approved to treat this form of solid tumor cancer. " The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 20, 2024 Category: Pharmaceuticals Source Type: news

FDA Grants Accelerated Approval for Amtagvi (lifileucel) for the Treatment of Advanced Melanoma
SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 19, 2024 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Treatment for Advanced Melanoma, Amtagvi
MONDAY, Feb. 19, 2024 -- The U.S. Food and Drug Administration has approved a novel treatment for advanced melanoma, the most deadly form of skin cancer. Amtagvi, made by Iovance Biotherapeutics Inc., becomes the first cellular therapy approved to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 19, 2024 Category: General Medicine Source Type: news